The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
CRISPR–Cas9 epigenome editing enables high-throughput screening for functional regulatory elements in the human genome
Open accessAbstract
Large genome-mapping consortia and thousands of genome-wide association studies have identified non-protein-coding elements in the genome as having a central role in various biological processes. However, decoding the functions of the millions of putative regulatory elements discovered in these studies remains challenging. CRISPR-Cas9-based epigenome editing technologies have enabled precise perturbation of the activity of specific regulatory elements. Here we describe CRISPR-Cas9-based epigenomic regulatory element screening (CERES) for improved high-throughput screening of regulatory element activity in the native genomic context. Using dCas9 KRAB repressor and dCas9 p300 activator constructs and lentiviral single guide RNA libraries to target DNase I hypersensitive sites surrounding a gene of interest, we carried out both loss- and gain-of-function screens to identify regulatory elements for the β-globin and HER2 loci in human cells. CERES readily identified known and previously unidentified regulatory elements, some of which were dependent on cell type or direction of perturbation. This technology allows the high-throughput functional annotation of putative regulatory elements in their native chromosomal context.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Activating domains (dCas9–VPR or dCas9–p300) have also been used to scan for poised enhancers in an approach termed CRISPR activation or ‘CRISPRa’92,208(Figure 2d).”
From Towards a comprehensive catalogue of validated and target-linked human enhancers (2020) · cites this paper as [208]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“When comparing Borzoi, Enformer and a distance-to-TSS baseline on their ability to classify measured positive from negative enhancer–gene interactions in data from previous works60–65, we find that Borzoi has superior average precision (AUPRC) and area under the receiver operating characteristic curve (AUROC) at all distances (Fig. 4c and Extended Data Fig. 5a).”
From Predicting RNA-seq coverage from DNA sequence as a unifying model of gene regulation (2025) · cites this paper as [62]
The cited source says what the claim attributes to it.
In the citing paper
“CRISPRi has subsequently been used in multiple single-gene screens of regulatory elements105,208,209.”
From Towards a comprehensive catalogue of validated and target-linked human enhancers (2020) · cites this paper as [208]
In the citing paper
“we validated 4 out of 5 enhancers identified in a CRISPRi screen for HBE1 enhancers using a fluorescent reporter22”
From Targeted Perturb-seq enables genome-scale genetic screens in single cells (2020) · cites this paper as [22]
In the citing paper
“15 gRNAs targeting the HBE1 TSS, and HS1–4 of the Globin LCR were chosen as validated from Klann et al. (2017) and Xie et al. (2017).”
From A Genome-wide Framework for Mapping Gene Regulation via Cellular Genetic Screens (2019) · cites this paper as Klann et al. (2017)
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
Fast gapped-read alignment with Bowtie 2
Langmead, B., & Salzberg, S. L. (2012) · Nature Methods · doi:10.1038/nmeth.1923 · Cited by 56,400
An integrated encyclopedia of DNA elements in the human genome
The ENCODE Project Consortium (2012) · Nature · doi:10.1038/nature11247 · Cited by 18,072
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
RNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
Improved vectors and genome-wide libraries for CRISPR screening
Sanjana, N. E., Shalem, O., & Zhang, F. (2014) · Nature Methods · doi:10.1038/nmeth.3047 · Cited by 5,239
Genome-scale CRISPR-Cas9 knockout screening in human cells
Shalem, O., Sanjana, N. E., Hartenian, E., Shi, X., Scott, D. A., Mikkelsen, T. S., Heckl, D., Ebert, B. L., Root, D. E., Doench, J. G., et al. (2014) · Science · doi:10.1126/science.1247005 · Cited by 5,234
Repurposing CRISPR as an RNA-Guided Platform for Sequence-Specific Control of Gene Expression
Qi, L. S., Larson, M. H., Gilbert, L. A., Doudna, J. A., Weissman, J. S., Arkin, A. P., & Lim, W. A. (2013) · Cell · doi:10.1016/j.cell.2013.02.022 · Cited by 5,016
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–200 of 454
Zhong, X., Prinz, A., Steger, J., García-Cuéllar, M.-P., Radsak, M. P., Bentaher, A., & Slany, R. K. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018025866 · Cited by 52
DNA Methylation Editing by CRISPR-guided Excision of 5-Methylcytosine
Devesa-Guerra, I., Morales‐Ruíz, T., Pérez-Roldán, J., Parrilla-Doblas, J. T., León, M. D., García‐Ortiz, M. V., Ariza, R. R., & Roldán‐Arjona, T. (2020) · Journal of Molecular Biology · doi:10.1016/j.jmb.2020.02.007 · Cited by 51
Targeting cancer epigenetics with CRISPR-dCAS9: Principles and prospects
Rahman, M. M., & Tollefsbol, T. O. (2020) · Methods · doi:10.1016/j.ymeth.2020.04.006 · Cited by 51
Moreb, E. A., Hoover, B., Yaseen, A., Valyasevi, N., Roecker, Z. A., Menacho‐Melgar, R., & Lynch, M. (2017) · ACS Synthetic Biology · doi:10.1021/acssynbio.7b00174 · Cited by 51
In vivo epigenome editing and transcriptional modulation using CRISPR technology
Lau, C., & Suh, Y. (2018) · Transgenic Research · doi:10.1007/s11248-018-0096-8 · Cited by 51
CRISPR-SURF: discovering regulatory elements by deconvolution of CRISPR tiling screen data
Hsu, J. Y., Fulco, C. P., Cole, M. A., Canver, M. C., Pellin, D., Sher, F., Farouni, R., Clement, K., Guo, J. A., Biasco, L., et al. (2018) · Nature Methods · doi:10.1038/s41592-018-0225-6 · Cited by 53
Gjaltema, R. A. F., Schwämmle, T., Kautz, P., Robson, M. I., Schöpflin, R., Lustig, L. R., Brandenburg, L., Dunkel, I., Vechiatto, C., Ntini, E., et al. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.11.023 · Cited by 48
Epigenetic basis and targeting of cancer metastasis
Banerjee, R., Smith, J., Eccles, M. R., Weeks, R. J., & Chatterjee, A. (2021) · Trends in cancer · doi:10.1016/j.trecan.2021.11.008 · Cited by 51
Luo, R., Yan, J., Oh, J. W., Wang, X., Shigaki, D., Wong, W., Cho, H., Murphy, D., Cutler, R. R., Rosen, B. P., et al. (2023) · Nature Genetics · doi:10.1038/s41588-023-01450-7 · Cited by 50
Zhou, Z., Ruiz‐Cantu, L., Chen, X., Alexander, M. R., Roberts, C. J., Hague, R., Tuck, C. J., Irvine, D. J., & Wildman, R. D. (2019) · Additive manufacturing · doi:10.1016/j.addma.2019.100792 · Cited by 49
Modeling the complex genetic architectures of brain disease
Fernando, M. B., Ahfeldt, T., & Brennand, K. (2020) · Nature Genetics · doi:10.1038/s41588-020-0596-3 · Cited by 48
Jeffries, M. A. (2018) · Clinical Immunology · doi:10.1016/j.clim.2018.02.001 · Cited by 51
Bidirectional epigenetic editing reveals hierarchies in gene regulation
Pacalin, N. M., Steinhart, Z., Shi, Q., Belk, J. A., Dorovskyi, D., Kraft, K., Parker, K. R., Shy, B. R., Marson, A., & Chang, H. Y. (2024) · Nature Biotechnology · doi:10.1038/s41587-024-02213-3 · Cited by 49
Liu, B., He, X., Zhuo, R., & Cheng, S. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.10.018 · Cited by 46
Lau, C., Ho, J. W., Lo, P. K., & Tin, C. (2019) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2019.04.015 · Cited by 46
Identification of functional regulatory elements in the human genome using pooled CRISPR screens
Borys, S. M., & Younger, S. T. (2020) · BMC Genomics · doi:10.1186/s12864-020-6497-0 · Cited by 45
Comparative analysis of dCas9-VP64 variants and multiplexed guide RNAs mediating CRISPR activation
Omachi, K., & Miner, J. H. (2022) · PLoS ONE · doi:10.1371/journal.pone.0270008 · Cited by 48
Technologies and Computational Analysis Strategies for CRISPR Applications
Clement, K., Hsu, J. Y., Canver, M. C., Joung, J. K., & Pinello, L. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.06.012 · Cited by 45
Lipid-based nanocarrier mediated CRISPR/Cas9 delivery for cancer therapy
Aziz, A., Rehman, U., Sheikh, A., Abourehab, M. A. S., & Kesharwani, P. (2022) · Journal of Biomaterials Science Polymer Edition · doi:10.1080/09205063.2022.2121592 · Cited by 47
CRISPR Screens in Synthetic Lethality and Combinatorial Therapies for Cancer
Castells‐Roca, L., Tejero, E., Rodríguez‐Santiago, B., & Surrallés, J. (2021) · Cancers · doi:10.3390/cancers13071591 · Cited by 45
Castrillo, J. I., Lista, S., Hampel, H. J., & Ritchie, C. W. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-7704-8_3 · Cited by 44
Turakhia, Y., Goenka, S. D., Bejerano, G., & Dally, W. J. (2019) · IEEE International Symposium on High-Performance Computer Architecture (HPCA) · doi:10.1109/hpca.2019.00050 · Cited by 41
Mechanosensitive genomic enhancers potentiate the cellular response to matrix stiffness
Cosgrove, B. D., Bounds, L. R., Taylor, C. K., Su, A. L., Rizzo, A. J., Barrera, A., Sun, T., Safi, A., Song, L., Whitlow, T. J., et al. (2025) · Science · doi:10.1126/science.adl1988 · Cited by 43
Self-citationKhademi, Z., Ramezani, M., Alibolandi, M., Zirak, M. R., Salmasi, Z., Abnous, K., & Taghdisi, S. M. (2022) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2022.119691 · Cited by 44
CRISPR screen in mechanism and target discovery for cancer immunotherapy
Liu, D., Zhao, X., Tang, A., Xu, X., Liu, S., Zha, L., Ma, W., Zheng, J., & Shi, M. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188378 · Cited by 44
Loop competition and extrusion model predicts CTCF interaction specificity
Wang, X., & Beer, M. (2021) · Nature Communications · doi:10.1038/s41467-021-21368-0 · Cited by 40
Combinatorial chromatin dynamics foster accurate cardiopharyngeal fate choices
Racioppi, C., Wiechecki, K., & Christiaen, L. (2019) · eLife · doi:10.7554/elife.49921 · Cited by 36
Chen, M., He, X., Guo, Y., Hu, J., Liang, B., Zeng, K., & Yang, G. (2020) · Polymer Chemistry · doi:10.1039/d0py01322f · Cited by 38
Adeno-associated virus gene replacement for recessive inner ear dysfunction: Progress and challenges
Askew, C., & Chien, W. W. (2020) · Hearing Research · doi:10.1016/j.heares.2020.107947 · Cited by 36
Lensch, S., Herschl, M. H., Ludwig, C., Sinha, J., Hinks, M. M., Mukund, A. X., Fujimori, T., & Bintu, L. (2022) · eLife · doi:10.7554/elife.75115 · Cited by 36
ASPSCR1::TFE3 orchestrates the angiogenic program of alveolar soft part sarcoma
Tanaka, M., Chuaychob, S., Homme, M., Yamazaki, Y., Lyu, R., Yamashita, K., Ae, K., Matsumoto, S., Kumegawa, K., Maruyama, R., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37049-z · Cited by 37
Lopes, R., Sprouffske, K., Sheng, C., Uijttewaal, E., Wesdorp, A. E., Dahinden, J., Wengert, S., Díaz-Miyar, J., Yildiz, U., Bleu, M., et al. (2021) · Science Advances · doi:10.1126/sciadv.abf5733 · Cited by 31
MAUDE: inferring expression changes in sorting-based CRISPR screens
de Boer, C. G., Ray, J. P., Hacohen, N., & Regev, A. (2020) · Genome biology · doi:10.1186/s13059-020-02046-8 · Cited by 39
Chromatin Remodeling of Colorectal Cancer Liver Metastasis is Mediated by an HGF‐PU.1‐DPP4 Axis
Wang, L., Wang, E., Balcazar, J. P., Wu, Z., Xiang, K., Wang, Y., Huang, Q., Negrete, M., Chen, K., Li, W., et al. (2021) · Advanced Science · doi:10.1002/advs.202004673 · Cited by 34
Self-citationAdvancing biotechnology with CRISPR/Cas9: recent applications and patent landscape
Ferreira, R., David, F., & Nielsen, J. (2018) · Journal of Industrial Microbiology & Biotechnology · doi:10.1007/s10295-017-2000-6 · Cited by 33
Cohesin-mediated 3D contacts tune enhancer-promoter regulationPreprint
Guckelberger, P., Doughty, B. R., Munson, G., Rao, S. S. P., Tan, Y., Cai, X. S., Fulco, C. P., Nasser, J., Mualim, K. S., Bergman, D. T., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.07.12.603288 · Cited by 33
Riegel, D., Romero-Fernández, E., Simon, M., Adenugba, A., Singer, K., Mayr, R., Weber, F., Kleemann, M., Imbusch, C. D., Kreutz, M. P., et al. (2023) · Molecular Cell · doi:10.1016/j.molcel.2022.12.029 · Cited by 35
Ray-Jones, H., Duffus, K., McGovern, A., Martin, P., Shi, C., Hankinson, J., Gough, O., Yarwood, A., Morris, A. P., Adamson, A., et al. (2020) · BMC Biology · doi:10.1186/s12915-020-00779-3 · Cited by 31
Disruptive Technology: CRISPR/Cas-Based Tools and Approaches
Patsali, P., Kleanthous, M., & Lederer, C. W. (2019) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-019-00391-4 · Cited by 31
Histone modifications, DNA methylation, and the epigenetic code of alcohol use disorder
Bohnsack, J. P., & Pandey, S. C. (2020) · International review of neurobiology · doi:10.1016/bs.irn.2020.08.005 · Cited by 32
Chemical Control of a CRISPR-Cas9 Acetyltransferase
Shrimp, J. H., Grose, C., Widmeyer, S. R. T., Thorpe, A. L., Jadhav, A., & Meier, J. L. (2018) · ACS Chemical Biology · doi:10.1021/acschembio.7b00883 · Cited by 30
EMT signaling: potential contribution of CRISPR/Cas gene editing
Mohammadinejad, R., Biagioni, A., Arunkumar, G., Shapiro, R. S., Chang, K., Sedeeq, M., Taiyab, A., Hashemabadi, M., Pardakhty, A., Mandegary, A., et al. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03449-3 · Cited by 31
Using CRISPR to understand and manipulate gene regulation
Akıncı, E., Hamilton, M. C., Khowpinitchai, B., & Sherwood, R. I. (2021) · Development · doi:10.1242/dev.182667 · Cited by 36
Augmenting and directing long-range CRISPR-mediated activation in human cells
Tak, Y. E., Horng, J. E., Perry, N. T., Schultz, H. T., Iyer, S., Yao, Q., Zou, L. S., Aryee, M. J., Pinello, L., & Joung, J. K. (2021) · Nature Methods · doi:10.1038/s41592-021-01224-1 · Cited by 28
Enhancement of protein translation by CRISPR/dCasRx coupled with SINEB2 repeat of noncoding RNAs
Cao, C., Li, A., Xu, C., Wu, B., Liu, J., & Liu, Y. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad010 · Cited by 28
Harnessing the evolving CRISPR/Cas9 for precision oncology
Li, T., Li, S., Kang, Y., Zhou, J., & Yi, M. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05570-4 · Cited by 35
Gene activation by dCas9-CBP and the SAM system differ in target preference
Sajwan, S., & Mannervik, M. (2019) · Scientific Reports · doi:10.1038/s41598-019-54179-x · Cited by 29
Advance genome editing technologies in the treatment of human diseases: CRISPR therapy (Review)
Alagöz, M., & Kherad, N. (2020) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2020.4609 · Cited by 32
Parallel characterization of cis-regulatory elements for multiple genes using CRISPRpath
Ren, X., Wang, M., Li, B., Jamieson, K., Zheng, L., Jones, I. R., Li, B., Takagi, M. A., Lee, J., Maliskova, L., et al. (2021) · Science Advances · doi:10.1126/sciadv.abi4360 · Cited by 28
Ren, G., Lai, B., Harly, C., Baek, S., Ding, Y., Zheng, M., Cao, Y., Cui, K., Yu, Y., Zhu, J., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.06.019 · Cited by 30
Identifying Novel Enhancer Elements with CRISPR-Based Screens
Klein, J. C., Chen, W., Gasperini, M. J., & Shendure, J. (2018) · ACS Chemical Biology · doi:10.1021/acschembio.7b00778 · Cited by 33
CRISPR Tools for Systematic Studies of RNA RegulationPreprint
Engreitz, J., Abudayyeh, O. O., Gootenberg, J. S., & Zhang, F. (2019) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a035386 · Cited by 31
Epigenetic editing: from concept to clinic
Heller, E. A., Bintu, L., & Rots, M. G. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01323-0 · Cited by 37
Epigenetic therapy of novel tumour suppressor ZAR1 and its cancer biomarker function
Deutschmeyer, V. E., Breuer, J., Walesch, S. K., Sokòl, A. M., Graumann, J., Bartkuhn, M., Boettger, T., Roßbach, O., & Richter, A. M. (2019) · Clinical Epigenetics · doi:10.1186/s13148-019-0774-2 · Cited by 28
CRISPR: A new paradigm of theranostics
Yadav, N., Narang, J., Chhillar, A. K., & Rana, J. S. (2021) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2020.102350 · Cited by 31
The evolution and history of gene editing technologies
Randhawa, S., & Sengar, S. (2021) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2021.01.002 · Cited by 31
Maybury‐Lewis, S. Y., Brown, A. K., Yeary, M., Sloutskin, A., Dhakal, S., Juven‐Gershon, T., & Webb, A. E. (2021) · Aging Cell · doi:10.1111/acel.13499 · Cited by 27
Activation of the imprinted Prader-Willi syndrome locus by CRISPR-based epigenome editing
Rohm, D., Black, J. B., McCutcheon, S. R., Barrera, A., Berry, S. S., Morone, D. J., Nuttle, X., de Esch, C. E., Tai, D. J. C., Talkowski, M. E., et al. (2025) · Cell Genomics · doi:10.1016/j.xgen.2025.100770 · Cited by 28
Self-citationCRISPR Technology for Breast Cancer: Diagnostics, Modeling, and Therapy
Mintz, R. L., Gao, M. A., Lo, K., Lao, Y., Li, M., & Leong, K. W. (2018) · Advanced Biosystems · doi:10.1002/adbi.201800132 · Cited by 27
Epigenome editing by CRISPR/Cas9 in clinical settings: possibilities and challenges
Pei, W., Zhang, Y., Yin, T., & Yu, Y. (2019) · Briefings in Functional Genomics · doi:10.1093/bfgp/elz035 · Cited by 28
CRISPR/dCas system as the modulator of gene expression
Kazi, T. A., & Biswas, S. R. (2021) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2020.12.002 · Cited by 28
Integrative analysis of epigenetics data identifies gene-specific regulatory elements
Schmidt, F., Marx, A., Baumgarten, N., Hebel, M., Wegner, M., Kaulich, M., Leisegang, M. S., Brandes, R. P., Göke, J., Vreeken, J., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab798 · Cited by 25
High-throughput genetic screens using CRISPR–Cas9 system
Kweon, J., & Kim, Y. (2018) · Archives of Pharmacal Research · doi:10.1007/s12272-018-1029-z · Cited by 27
Decoding the noncoding genome via large-scale CRISPR screens
Shukla, A., & Huangfu, D. (2018) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2018.06.001 · Cited by 27
Physiology Based Approaches for Breeding of Next-Generation Food Legumes
Shunmugam, A. S. K., Kannan, U., Jiang, Y., Daba, K. A., & Gorim, L. Y. (2018) · Plants · doi:10.3390/plants7030072 · Cited by 29
Epigenetic Control of a Local Chromatin Landscape
Chiarella, A. M., Lu, D., & Hathaway, N. A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21030943 · Cited by 31
Innovative Precision Gene‐Editing Tools in Personalized Cancer Medicine
Dai, X., Blancafort, P., Wang, P., Sgro, A., Thompson, E. W., & Ostrikov, K. (2020) · Advanced Science · doi:10.1002/advs.201902552 · Cited by 28
How to Completely Squeeze a Fungus—Advanced Genome Mining Tools for Novel Bioactive Substances
Schüller, A., Studt, L., & Strauss, J. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091837 · Cited by 26
Aherrahrou, R., Reinberger, T., Hashmi, S., & Erdmann, J. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvae161 · Cited by 25
Farhang, N., Davis, B. J., Weston, J. D., Ginley-Hidinger, M., Gertz, J., & Bowles, R. D. (2020) · Tissue Engineering Part A · doi:10.1089/ten.tea.2020.0062 · Cited by 25
Phenotypic novelty by CRISPR in plants
Liu, C., & Moschou, P. N. (2018) · Developmental Biology · doi:10.1016/j.ydbio.2018.01.015 · Cited by 25
Human Organoids as an Emerging Tool for Genome Screenings
Andreatta, F., Hendriks, D. F. G., & Artegiani, B. (2025) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-103023-122327 · Cited by 24
Synthetic transcription factors for cell fate reprogramming
Black, J. B., & Gersbach, C. A. (2018) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2018.05.001 · Cited by 24
Self-citationBreunig, C., Köferle, A., Neuner, A. M., Wiesbeck, M. F., Baumann, V., & Stricker, S. H. (2020) · Physiological Reviews · doi:10.1152/physrev.00034.2019 · Cited by 27
Profiling of H3K27Ac Reveals the Influence of Asthma on the Epigenome of the Airway Epithelium
McErlean, P. K., Kelly, A., Dhariwal, J., Kirtland, M., Watson, J., Ranz, I., Smith, J. L., Saxena, A., Cousins, D. J., van Oosterhout, A. J. M., et al. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.585746 · Cited by 29
Margiotta‐Casaluci, L., Owen, S. F., & Winter, M. J. (2023) · Environmental Toxicology and Chemistry · doi:10.1002/etc.5634 · Cited by 24
CRISPR editing in biological and biomedical investigation
Huang, J., Wang, Y., & Zhao, J. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.26141 · Cited by 25
Zhang, Y., Hyle, J. W., Wright, S., Shao, Y., Zhao, X., Zhang, H., & Li, C. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1909720116 · Cited by 24
Aneuploidy in human cancer: new tools and perspectives
Lakhani, A. A., Thompson, S. L., & Sheltzer, J. M. (2023) · Trends in Genetics · doi:10.1016/j.tig.2023.09.002 · Cited by 24
Applications of CRISPR-Cas in Bioengineering, Biotechnology, and Translational Research
Lau, C. (2018) · The CRISPR Journal · doi:10.1089/crispr.2018.0026 · Cited by 22
Epigenome editing based treatment: Progresses and challenges
Yuan, L., Xiong, Y., Zhang, Y., Gu, S., & Lei, Y. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.08.047 · Cited by 30
Coukos, R., Yao, D., Sánchez, M. I., Strand, E. T., Olive, M. E., Udeshi, N. D., Weissman, J. S., Carr, S. A., Bassik, M. C., & Ting, A. Y. (2021) · eLife · doi:10.7554/elife.69142 · Cited by 21
CRISPR-Based Approaches for the High-Throughput Characterization of Long Non-Coding RNAs
Hazan, J. M., & Bester, A. C. (2021) · Non-Coding RNA · doi:10.3390/ncrna7040079 · Cited by 22
CRISPR/Cas9 technology: applications in oocytes and early embryos
Zhang, Y., Yin, T., & Zhou, L. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04610-9 · Cited by 26
A principled strategy for mapping enhancers to genes
Kim, D., An, H., Shearer, R. S., Sharif, M. A., Fan, C., Choi, J., Ryu, S., & Park, Y. (2019) · Scientific Reports · doi:10.1038/s41598-019-47521-w · Cited by 20
Activity-by-Contact model of enhancer specificity from thousands of CRISPR perturbationsPreprint
Fulco, C. P., Nasser, J., Jones, T. R., Munson, G., Bergman, D. T., Subramanian, V., Grossman, S. R., Anyoha, R., Patwardhan, T. A., Nguyen, T. H., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/529990 · Cited by 21
Zhao, Y., Zhang, M., & Yang, D. (2022) · Quantitative Biology · doi:10.15302/j-qb-022-0299 · Cited by 20
Yan, H., Xin, Z., Sang, Z., Li, X., Xie, J., Wu, J., Pang, S., Wen, Y., & Wang, W. (2025) · Nature Communications · doi:10.1038/s41467-025-57073-5 · Cited by 20
Li, Y., Tan, M., Akkari-Henić, A., Zhang, L. S., Kip, M., Sun, S., Sepers, J. J., Xu, N., Ariyürek, Y., Kloet, S. L., et al. (2024) · Nature Biomedical Engineering · doi:10.1038/s41551-024-01204-8 · Cited by 18
Naeem, M. S., Zaman, W., Saqib, S., Shahzad, A., Rahman, S. U., & Ahmad, N. (2024) · South African Journal of Botany · doi:10.1016/j.sajb.2024.07.038 · Cited by 23
The application of CRISPR/Cas9–based genome-wide screening to disease research
Chen, X., Zheng, M., Lin, S., Huang, M., Chen, S., & Chen, S. (2024) · Molecular and Cellular Probes · doi:10.1016/j.mcp.2024.102004 · Cited by 21
Chromatin Manipulation and Editing: Challenges, New Technologies and Their Use in Plants
Fal, K., Tomková, D., Vachon, G., Chabouté, M., Berr, A., & Carles, C. C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020512 · Cited by 19
Chen, H. V., Lorenzini, M. H., Lavalle, S. N., Sajeev, K., Fonseca, A., Fiaux, P. C., Sen, A., Luthra, I., Ho, A. J., Chen, A. R., et al. (2023) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2023.03.008 · Cited by 15
Specific multivalent molecules boost CRISPR-mediated transcriptional activation
Chen, R., Shi, X., Yao, X., Gao, T., Huang, G., Ning, D., Cao, Z., Xu, Y., Liang, W., Tian, S. Z., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-51694-y · Cited by 19
CRISPR-based methods for high-throughput annotation of regulatory DNA
Klann, T. S., Black, J. B., & Gersbach, C. A. (2018) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2018.02.004 · Cited by 19
Self-citationGrisard, E., Coan, M., Cesaratto, L., Rigo, I., Zandonà, L., Paulitti, A., Andreuzzi, E., Vinciguerra, G. L. R., Poletto, E., Ben, F. D., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.06.044 · Cited by 18
Robust and inducible genome editing via an all-in-one prime editor in human pluripotent stem cells
Wu, Y., Zhong, A., Sidharta, M., Kim, T. W., Ramirez, B., Persily, B., Studer, L., & Zhou, T. (2024) · Nature Communications · doi:10.1038/s41467-024-55104-1 · Cited by 22
Schrauben, M., Dempster, E. L., & Lunnon, K. (2020) · Brain Pathology · doi:10.1111/bpa.12881 · Cited by 17
Programming of Cell Resistance to Genotoxic and Oxidative Stress
Velegzhaninov, I. O., Ievlev, V., Игоревна, П. Я., Шадрин, Д. М., & Vakhrusheva, O. (2018) · Biomedicines · doi:10.3390/biomedicines6010005 · Cited by 16
El-Kenawy, A. E.-M., Benarba, B., Neves, A. F., Araújo, T. G., Tan, B. L., & Gouri, A. (2019) · EXCLI journal · doi:10.17179/excli2019-1833 · Cited by 16
Metadata
- Authors
- Klann, T. S., Black, J. B., Chellappan, M., Safi, A., Song, L., Hilton, I. B., Crawford, G. E., Reddy, T. E., & Gersbach, C. A.
- Affiliations
- Duke University (US)
- Corresponding author
- Crawford, Gregory E
- Reddy, Timothy E
- Gersbach, Charles A
- ORCID
- Venue
- Nature Biotechnology
- Published
- 2017-04-03
- Volume
- 35
- Issue
- 6
- Pages
- 561-568
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- PMC
- PMC5462860
- OpenAlex
- W2604130415
- Cited by
- 447
- References
- 56
- Citations by year
- 2026: 23 · 2025: 24 · 2024: 37 · 2023: 39 · 2022: 53 · 2021: 57 · 2020: 70 · 2019: 64 · 2018: 55 · 2017: 24
- FWCI
- 24.45
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Biotechnology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (1dp2od008586-01)
- National Institute on Drug Abuse (R01DA036865)
- National Human Genome Research Institute (U01HG007900)
- National Institute of General Medical Sciences (T32GM008555, R41GM119914)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (P30AR066527)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- regulatory elements, high-throughput screening, Ceres, DNase I hypersensitive sites, loss-of-function screen, gain-of-function screen, beta-globin locus, non-coding genome
- MeSH terms
- Gene Editing, Chromosome Mapping, Humans, Genome, Human, Sequence Analysis, DNA, Regulatory Elements, Transcriptional, Epigenomics, High-Throughput Nucleotide Sequencing, Clustered Regularly Interspaced Short Palindromic Repeats, CRISPR-Cas Systems, CRISPR-Associated Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
